EN DE
Watch Fuse Medical Inc for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Fuse Medical Inc (FZMD) fair value: what the stock is really worth

As of Nov 20, 2026: fair value (intrinsic value) of Fuse Medical Inc stock $0.039, price $0.03, upside +30.0%, quality 57 out of 100. Rating: undervalued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US36113U1016

FM Fuse Medical Inc logo Thin data Nov 7, 2026

Fuse Medical Inc

FZMD · US

Cheap (23% below fair value), solid company and rising price: meets all 3 rules.

Follow free in the weekly email
Fair value $0.039 · Undervalued 
Rising price (uptrend) 
Highly profitable · 21.6% net margin (TTM) 
Low debt 
Generates free cash flow 
Ranks above peers (11/12) 
Costs just 1.5 times its yearly profit. 
Quality 57/100 
Mixed Growth (revenue YoY −15.9 %/yr in USD) 
Changed on Nov 2: $0.048 → $0.039 
Narrow moat 43/100 · thin data
Thin data 
⚠ Thinly traded⚠ Small free float
Watch Fuse Medical Inc for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.8 $0.02 Fair Value $0.039 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range $0.02 – $0.8 · fair‑value band $0.033 – $0.039 · the $0.03 price screens below the $0.039 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow Fuse Medical in your weekly email

Every Wednesday you see whether Fuse Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Fuse Medical, Inc. manufactures and distributes medical devices in the United States.

Show moreShow less

The company provides orthopedic implants, including internal and external fixation products; upper and lower extremity plating and total joint reconstruction implants; soft tissue fixation and augmentation for sports medicine procedures; and full spinal implants for trauma, degenerative disc disease, and deformity indications.

It also provides osteo-biologics and regenerative products, which include human allografts, tendons, substitute bone materials, and regenerative tissues. The company serves hospitals, medical facilities, and sub-distributors. Fuse Medical, Inc. is based in Farmers Branch, Texas.

Stock analysis

Fuse Medical Inc (FZMD) currently trades at $0.03, while our model-based Fair Value estimate is $0.039, implying the stock looks roughly 23% undervalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $0.065 per share, and 19 of the 22 models we run sit above the $0.03 price.

Bear case: the Growth Earnings group reads lowest at $0.03, and 3 of the 22 models stay below the price. Data coverage for this calculation is low.

Scenario range: $0.033 (bear) to $0.039 (bull), the price of $0.03 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.

Fuse Medical Inc reported revenue of $9.0M in FY2025 versus $20.4M in FY2021, a compound −18.5%/yr. Reported net income was $137K in FY2025.

Key figures

Market cap $2.3M Micro · P/E ratio 1.5 · P/S ratio 0.13 · EPS (TTM) $0.02 · Net margin 21.6% · Return on assets (EBIT) −1.2% (5-year average) · Operating margin 7.4% · Revenue (TTM) $18.4M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).

What moves the price

The share trades about 57% below its 52-week high and 50% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at 30%, FZMD screens cheaper than that median.

Fair Value models

Bear $0.033 Fair Value $0.039 Bull $0.039
Price $0.03 · Upside +30.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 11 months old). Earnings retained since then ($0.0178 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $0.0400 $0.0600 $0.0900 80
Growth DCF $0.0500 $0.0600 $0.0900 79
Owner Earnings $0.0400 $0.0600 $0.0900 76
All 22 models by family
DCF Models
FCF DCF $0.0400 $0.0600 $0.0900 80
Owner Earnings $0.0400 $0.0600 $0.0900 76
5Y Revenue Exit $0.0400 $0.0700 $0.1000 72
5Y EBITDA Exit $0.0600 $0.0900 $0.1300 75
5Y P/E Exit $0.0300 $0.0500 $0.0600 71
10Y Revenue Exit $0.0400 $0.0600 $0.0800 67
10Y EBITDA Exit $0.0500 $0.0700 $0.1000 68
10Y P/E Exit $0.0400 $0.0500 $0.0600 65
Earnings-Based
Graham-Dodd $0.0100 $0.0200 $0.0200 67
EPV $0.0500 $0.0600 $0.0600 74
Multiples
P/E Multiple $0.0300 $0.0400 $0.0500 63
P/S Multiple $0.0200 $0.0300 $0.0400 57
P/B Multiple $0.2700 $0.3600 $0.4500 55
EV/EBIT $0.0400 $0.0600 $0.0800 65
EV/EBITDA $0.0500 $0.0700 $0.1000 66
EV/Revenue $0.0200 $0.0400 $0.0600 51
Asset-Based
NCAV (Graham) $0.0400 $0.0500 $0.0700 54
Growth DCF
Growth DCF $0.0500 $0.0600 $0.0900 79
Rev-Margin DCF $0.0400 $0.0700 $0.0900 73
Economic Profit
Residual Income $0.0600 $0.0600 $0.0700 71
ROIC Compounder $0.0500 $0.0600 $0.0600 72
Growth Earnings
Growth-Adj P/E $0.0200 $0.0300 $0.0400 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 57/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 40
How much profit the company makes from its sales and capital
Quality Growth 37
Are margins and returns getting better?
Cashflow 42
Do the profits arrive as real cash?
Financial strength 45
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 76
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 55
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
+0.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+0.0%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−5% → 4%
⚠ Revenue per share shrinking 6.5%/yr over ~10Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+14.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +11.9% a year for the price.

Watch FZMD, get fair value alerts →

Compare Fuse Medical Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 399 stocks

Beats the industry median on 11/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 57 · Above median
Fair Value upside +30.0% · Top 25%
Profitability
Return on assets 1.1% · Above median
Net margin (12 months) 21.6% · Top 25%
Operating margin (12 months) 7.4% · Above median
Growth and dividend
Revenue growth (quarter YoY) 7.0% · Below median
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (12 months) 1.5× · Cheapest 25%
P/B 0.35× · Cheapest 25%
P/S (12 months) 0.13× · Cheapest 25%
Price / free cash flow (fiscal year) 17.0× · Cheaper than median
EV/EBITDA 9.1× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)73 · sector 23
FUTURE (revenue growth)35 · sector 43
PAST (return on equity)0 · sector 1
HEALTH (low debt)99 · sector 97
DIVIDEND (yield)0 · sector 35

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
DexCom, Inc DXCM $79.32 $90.77 +14% vs FZMD
Boston Scientific Corporation BSX $41.98 $48.00 +14% vs FZMD
Stryker Corporation SYK $310.00 $344.39 +11% vs FZMD
STERIS plc STE $255.76 $283.15 +11% vs FZMD
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥183.81 ¥197.34 +7% vs FZMD
GE HealthCare Technologies Inc GEHC $80.64 $69.92 −13% vs FZMD
Edwards Lifesciences Corporation EW $101.85 $81.94 −20% vs FZMD
Medtronic plc MDT $99.94 $74.89 −25% vs FZMD
Abbott Laboratories, ABT $103.00 $75.28 −27% vs FZMD
Koninklijke Philips N.V PHIA €26.39 €15.23 −42% vs FZMD

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Fuse Medical Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Fuse Medical Inc Fair Value". https://www.fairvalue-calculator.com/stock/FZMD

Frequently asked questions

Is Fuse Medical Inc (FZMD) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $0.039 versus a price of $0.03, about +30% upside (undervalued).
What is the fair value of FZMD?
Our model-based fair value for Fuse Medical Inc is $0.039 (as of Nov 7, 2026), built from audited fundamentals. The current price: $0.03.
What is the quality score of FZMD?
Fuse Medical Inc has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Fuse Medical Inc (FZMD)?
We do not set a price target; the yardstick is the fair value of $0.039 (as of Nov 7, 2026) from 22 valuation models. Cautious scenario $0.033, optimistic scenario $0.039. It is a calculation from audited fundamentals, not an analyst target.
What is the Fuse Medical Inc stock forecast for 2026?
Our models put fair value at $0.039, about +30% upside versus a price of $0.03 (undervalued). Cautious scenario $0.033, optimistic scenario $0.039. The calculation is refreshed regularly with new filings.
What is the revenue of Fuse Medical Inc (FZMD)?
Fuse Medical Inc reported trailing-twelve-month revenue of about $18.4M (latest available figure, as of Nov 7, 2026).
What growth is priced into Fuse Medical Inc (FZMD)?
For today's price to be fair in a discounted-cash-flow model, Fuse Medical Inc would have to grow free cash flow by 14.6 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue fell 15.9 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of FZMD use?
Our models discount Fuse Medical Inc at 8.5 %: a base by market capitalisation (nano), damped by beta 0.45, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Fuse Medical Inc that is +14.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has Fuse Medical Inc (FZMD) delivered so far?
Over the past 5 years revenue at Fuse Medical Inc shrank 15.9 % a year. The price currently implies free-cash-flow growth of +14.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Fuse Medical Inc (FZMD) growing?
The median revenue growth in the sector is +7.4 % a year. That is the yardstick for the growth priced into Fuse Medical Inc (+14.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Fuse Medical Inc (FZMD)?
The free-cash-flow yield on the price is 5.88 %: that much free cash flow Fuse Medical Inc produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Fuse Medical Inc (FZMD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Fuse Medical Inc it is $0.039 per share (as of Nov 7, 2026), against a price of $0.03. It is the blended result of 22 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Fuse Medical Inc stock overvalued or undervalued in 2026?
As of Nov 7, 2026, FZMD trades below its calculated fair value: price $0.03, fair value $0.039, a gap of about +30% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of FZMD?
No. The price is what the market pays today ($0.03); the fair value is what the company's own numbers justify ($0.039). For Fuse Medical Inc the two are $0.009 per share apart. That gap is exactly why we show both numbers side by side.
How much is Fuse Medical Inc worth?
The market values Fuse Medical Inc at about $2.3M (market capitalisation, as of Nov 7, 2026). Per share that is $0.03; our models calculate a fair value of $0.039 per share.
What do the bullish and bearish scenarios say about FZMD?
Our models span a range for Fuse Medical Inc: cautious scenario $0.033, base $0.039, optimistic $0.039 per share (as of Nov 7, 2026, price $0.03). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of FZMD?
Fuse Medical Inc trades at a price-to-earnings ratio of 1.5 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.039 is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2016 to 2025), reported earnings: 9.3. Other multiples: P/B 0.4, P/S 0.1, EV/EBITDA 9.1.
How solid is the balance sheet of Fuse Medical Inc (FZMD)?
Balance-sheet figures for Fuse Medical Inc (as of Nov 7, 2026): debt of 0.03 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is FZMD from its 52-week high?
Fuse Medical Inc trades at $0.03, about 57% below its 52-week high of $0.07 and 50% above the low of $0.02 (as of Nov 20, 2026). Distance from the high says nothing about value: that is what the fair value of $0.039 is for.
Which stocks are comparable to Fuse Medical Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Fuse Medical Inc stock attractive at the current price?
The data as of Nov 7, 2026: price $0.03, calculated fair value $0.039 (+30%), Quality Score 57/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of FZMD calculated?
We run Fuse Medical Inc through 22 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $0.039 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 9.6% above its aggregate fair value. Fuse Medical Inc currently trades 23% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Fuse Medical Inc (FZMD)?
The closing price on Nov 20, 2026 was $0.03. Our model-based fair value is $0.039, about +30% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Fuse Medical Inc right now?
The price is below even our cautious bear case ($0.033). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (57/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of Fuse Medical Inc

How large is the market capitalisation of Fuse Medical Inc (FZMD)?
The market capitalisation of Fuse Medical Inc is $2.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Fuse Medical Inc (FZMD)?
The price-to-sales ratio of Fuse Medical Inc is 0.13 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Fuse Medical Inc (FZMD)?
Earnings per share at Fuse Medical Inc are $0.02 (price ÷ EPS = P/E 1.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Fuse Medical Inc (FZMD)?
The net margin of Fuse Medical Inc is 21.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Fuse Medical Inc (FZMD)?
On an EBIT basis the return on assets of Fuse Medical Inc is −1.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Fuse Medical Inc (FZMD)?
The operating margin of Fuse Medical Inc is 7.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Fuse Medical Inc (FZMD)?
Revenue at Fuse Medical Inc is growing 7.0% versus a year earlier (3y avg −21.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Fuse Medical Inc (FZMD)?
Earnings per share at Fuse Medical Inc are down 71.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Fuse Medical Inc (FZMD) carry?
The net debt of Fuse Medical Inc is $2.3M (fiscal year 2025, ≈ 16.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Fuse Medical Inc in the live analysis

One click puts Fuse Medical Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.